American College of Clinical Pharmacy
      Search      Cart

Highlights from the International Consensus Guidelines for the Optimal Use of the Polymyxins

Tuesday, October 23, 2018 from 10:15 AM to 11:45 AM PDT at Washington State Conference Center: Level Three, Tahoma 3&4

Available for 1.50 hours of CPE credit
Activity Number: 0217-0000-18-209-L01-P
Activity Type: A Knowledge-Based Activity

Join the guideline authors in an exciting discussion about the appropriate use of colistin and polymyxin B for the treatment of resistant gram-negative infections, including optimal dosing, monitoring, and use in special populations.

  • Jason M. Pogue, Pharm.D., BCPS-AQ IDSpeaker: Jason M. Pogue, Pharm.D., BCPS-AQ ID
    Clinical Pharmacist, Infectious Diseases, Sinai-Grace Hospital, Detroit, Michigan

  • Brian T. Tsuji, Pharm.D.Speaker: Brian T. Tsuji, Pharm.D.
    Professor and Director of Clinical Research, Department of Pharmacy Practice, University at Buffalo School of Pharmacy, Buffalo, New York

Learning Objectives
1. Define the mechanisms of action and resistance for the polymyxins.
2. Select optimal dosing and therapeutic drug monitoring of colistin and polymyxin B in typical and special patient populations.
3. Describe charactersitics of the polymxyins that make combination therapy with these agents appealing.
4. Discuss guideline recommendations for monotherapy versus combination therapy for carbapenem-resistant Gram-neagtive organisms..